A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered to patients with chemoimmunotherapy-resistant follicular lymphoma (FL).
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: PCI-32765 (Ibrutinib)
Eligibility
Inclusion Criteria:
- Histologic proof of Grade 1, 2, or 3a follicular lymphoma (FL) without clinical or
pathological evidence of transformation
- Previously treated with at least 2 prior lines of therapy, including at least 1
rituximab combination chemotherapy regimen; last prior line of therapy includes an
anti CD20 monoclonal antibody-containing chemotherapy regimen (separate lines of
therapy are defined as different regimens that are either separated by disease
progression, refractory disease, or relapsed disease)
- Resistant disease to the last therapy, defined as progression of disease during or
within 12 months of the last dose of chemotherapy in a CD20 antibody combination
chemotherapy regimen
- At least 1 measurable site of disease according to International Working Group Revised
Response Criteria for Malignant Lymphoma
- Eastern Cooperative Oncology Group performance status grade 0 or 1
- Hematology and biochemical laboratory values must be within protocol-defined
parameters within 7 days prior to enrollment
- Agrees to protocol-defined use of effective contraception
- Women of childbearing potential must have a negative serum or urine pregnancy test at
screening
Exclusion Criteria:
- Prior nitrosoureas within 6 weeks, chemotherapy within 3 weeks, therapeutic anticancer
antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation
therapy or other investigational agents within 3 weeks, or major surgery within 4
weeks of first dose of study drug
- Prior treatment with PCI-32765 or other Bruton's tyrosine kinase inhibitors (patients
who progressed or became refractory while on treatment with PI3K inhibitors are
excluded)
- Concurrent enrollment in another therapeutic investigational clinical treatment study
- Received a prior allogeneic hematopoietic stem cell transplant (prior autologous
hematopoietic stem cell transplant is allowed)
- Known central nervous system lymphoma
- History of prior malignancy (except malignancy treated with curative intent and with
no known active disease present for >=3 years before enrollment, adequately treated
non-melanoma skin cancer or lentigo maligna without evidence of disease, or adequately
treated cervical carcinoma in situ without evidence of disease)
- History of stroke or intracranial hemorrhage within 6 months prior to enrollment
- Requires anticoagulation with warfarin or equivalent vitamin K antagonists
- Requires treatment with strong cytochrome P450 (CYP)3A4/5 inhibitors
- Clinically significant cardiovascular disease such as uncontrolled or symptomatic
arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by
the New York Heart Association Functional Classification
- Known history of Human Immunodeficiency Virus (HIV) or active infection with Hepatitis
C or active infection with Hepatitis B or any uncontrolled active systemic infection
requiring intravenous antibiotics
- Women who are pregnant or breastfeeding
- Any life-threatening illness, medical condition, or organ system dysfunction which, in
the investigator's opinion, could compromise the patient's safety, interfere with the
absorption or metabolism of PCI-32765 capsules, or put the study outcomes at undue
risk
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting
Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation, mobile application development, and pharmaceutical trials.
Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.